Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review
posted on 2020-07-02, 11:13authored byGiulio Metro, Sara Baglivo, Riccardo Moretti, Guido Bellezza, Angelo Sidoni, Fausto Roila
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).